Yousif Capital Management LLC Sells 2,325 Shares of AdaptHealth Corp. (NASDAQ:AHCO)

Yousif Capital Management LLC trimmed its position in AdaptHealth Corp. (NASDAQ:AHCO) by 5.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 41,107 shares of the company’s stock after selling 2,325 shares during the period. Yousif Capital Management LLC’s holdings in AdaptHealth were worth $300,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC purchased a new stake in AdaptHealth in the third quarter worth $100,000. Raymond James & Associates purchased a new stake in AdaptHealth in the third quarter worth $101,000. Everence Capital Management Inc. purchased a new stake in AdaptHealth in the fourth quarter worth $102,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in AdaptHealth by 53.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,507 shares of the company’s stock worth $132,000 after purchasing an additional 5,073 shares during the period. Finally, Corton Capital Inc. purchased a new stake in AdaptHealth in the third quarter worth $147,000. 82.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at AdaptHealth

In related news, major shareholder James E. Flynn sold 182,607 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the sale, the insider now directly owns 11,643,769 shares of the company’s stock, valued at $128,314,334.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other AdaptHealth news, major shareholder James E. Flynn sold 52,487 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $10.93, for a total value of $573,682.91. Following the transaction, the insider now owns 11,826,376 shares of the company’s stock, valued at $129,262,289.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder James E. Flynn sold 182,607 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $11.02, for a total value of $2,012,329.14. Following the completion of the transaction, the insider now directly owns 11,643,769 shares in the company, valued at approximately $128,314,334.38. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by insiders.

AdaptHealth Trading Up 3.3 %

AdaptHealth stock opened at $10.60 on Tuesday. The company has a debt-to-equity ratio of 1.44, a current ratio of 1.21 and a quick ratio of 1.00. AdaptHealth Corp. has a one year low of $6.37 and a one year high of $15.37. The stock has a market capitalization of $1.41 billion, a PE ratio of -2.00, a price-to-earnings-growth ratio of 0.67 and a beta of 1.06. The business’s fifty day moving average is $10.38 and its 200 day moving average is $8.56.

AdaptHealth (NASDAQ:AHCO) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.20 by $0.44. AdaptHealth had a positive return on equity of 8.84% and a negative net margin of 21.21%. The company had revenue of $858.23 million for the quarter, compared to analysts’ expectations of $825.94 million. On average, sell-side analysts predict that AdaptHealth Corp. will post 0.88 EPS for the current year.

Analysts Set New Price Targets

AHCO has been the topic of several recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $13.00 price target on shares of AdaptHealth in a research note on Monday, March 4th. Jefferies Financial Group cut AdaptHealth from a “buy” rating to a “hold” rating and cut their target price for the stock from $14.50 to $8.00 in a research note on Monday, January 8th. UBS Group increased their target price on AdaptHealth from $9.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Finally, Truist Financial increased their target price on AdaptHealth from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $12.10.

AdaptHealth Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.